You are now leaving Neulasta.com

The sponsor of this site is not responsible for the content on the site you are about to enter.

CANCEL CONTINUE

You are going to a website that contains clinical information and was created specifically for healthcare professionals. If you are not a healthcare professional, and would like to return to the consumer site, please click CANCEL.

CANCEL CONTINUE

Tell A Friend

To send a link from Neulasta.com to someone you know, please complete the form.

All fields must be completed.

Please correct the errors below and try again.
Sending Email
We will not use the information you have provided for any purpose other than to send this email.

Thank You!

The address of this page
has been forwarded successfully.

CLICK TO CONTINUE

Important Safety Information

Who should not take Neulasta®?

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim (Neulasta®) or to filgrastim (Neupogen®).

What should I tell my health care provider before taking Neulasta®? Tell your healthcare provider if you:

  • Have sickle cell trait or sickle cell disease
  • Have had severe skin reactions to acrylic adhesives
  • Are allergic to latex
  • Have any other medical problems
  • Are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are possible serious side effects of Neulasta®?

  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta. A ruptured spleen can cause death. Call your doctor right away if you have pain in the left upper stomach area or left shoulder tip area. This pain could mean your spleen is enlarged or ruptured.
  • A serious lung problem called acute respiratory distress syndrome (ARDS). Call your health care provider or get emergency medical help right away if you get any of these symptoms of ARDS: fever, shortness of breath, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Get emergency medical help right away if you get any of these symptoms of a serious allergic reaction with Neulasta: shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, sweating, and hives. If you have an allergic reaction during the delivery of Neulasta, remove the On-body Injector for Neulasta by grabbing the edge of the adhesive pad and peeling off the On-body Injector for Neulasta. Get emergency medical help right away.
  • Sickle Cell Crises. Severe sickle cell crises, and sometimes death, can happen in people with sickle cell trait or disease who receive filgrastim, a medicine similar to Neulasta.

The most common side effect of Neulasta is pain in the bones and in your arms and legs.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Neulasta. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information about Neulasta, talk with your healthcare provider or pharmacist; go to www.neulasta.com, or call 1-844-696-3852 (1-844-MYNEULASTA).

Please see the Neulasta Patient Information for additional information.

Indication

Neulasta® (pegfilgrastim) is a prescription medication used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.

It is not known if Neulasta is safe and effective in children.

Talk With Your Doctor Before
Starting Strong Chemotherapy

Talk with your doctor about your possible infection risk before starting your chemotherapy. If you’ll be receiving strong chemotherapy, your doctor may prescribe a white blood cell booster, such as Neulasta®.1 Your doctor may prescribe Neulasta® starting with your first cycle of chemo and with every cycle, including your last. In a key clinical study, a low white blood cell count with fever—also called a neutropenic fever or febrile neutropenia—happened through all cycles of chemo, but happened most often in the first cycle of chemo.2

Understand your risk of infection

If you are on strong chemotherapy, you may have a greater chance of developing a low white blood cell count or infection if any of the following apply to you:

  • You are 65 or older.3
  • You previously developed a low white blood cell count while being treated with strong chemo.3
  • You already have a low white blood cell count while being treated with strong chemo.3
  • Your cancer has spread to your bone marrow.3
  • You've had strong chemotherapy or radiation before.4
  • You have medical conditions like diabetes, liver or heart diseases.4
  • You have late stage or stage 4 cancer.4

Questions to ask your doctor about infection risk with
chemotherapy

The questions below can help you start a discussion with your doctor about low white blood counts and risk of infection. You may find it helpful to print out these questions and take them with you on your next visit.

  • Which people on strong chemotherapy have an increased risk of developing neutropenia and infections?
  • Why does some chemotherapy increase my risk of infection?
  • What effect can a low white blood cell count or an infection have on me?
  • What are blood counts?
  • How are blood counts measured?
  • Should I keep track of my blood counts during chemotherapy?
  • How can I keep track of my blood counts?
  • What happens if I get a neutropenic fever?

EXPLORE HELPFUL RESOURCES

Reach out for information and support during chemotherapy

PATIENT STORIES

Real patients with cancer share their stories

  1. Neulasta® (pegfilgrastim) Prescribing Information, Amgen.
  2. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. J Clin Oncol. 2005;23:1178-1184.
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid Growth Factors V.2.2014 © National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed May 27, 2014. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all otherNCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  4. Lyman G H. JNCCN. 2005;3:557–571.